儿童难治性重症肌无力的治疗进展
Progress in the Treatment of Refractory Myasthenia Gravis in Children
DOI: 10.12677/acm.2026.1631086, PDF,   
作者: 甘校铭, 曹 洁*：重庆医科大学附属儿童医院全科医学科，儿童少年健康与疾病国家临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童神经发育与认知障碍重庆市重点实验室，重庆
关键词: 儿童重症肌无力；难治性；生物制剂；CAR-T细胞疗法；胸腺切除术；Myasthenia Gravis in Children； Refractory； Biological Agents； CAR-T Cell Therapy； Thymectomy
摘要: 重症肌无力(MG)是一种由多种抗体介导、细胞和体液免疫依赖、补体和细胞因子参与的神经–肌肉接头传递障碍的自身免疫性疾病。儿童MG在治疗上与成人有较大区别，而且目前临床仍缺乏针对儿童难治性MG统一的治疗方案。近年来，随着对MG发病机制进一步了解、新药物的研发应用、新理念的形成，给儿童难治性MG的诊疗带来了革命性的变化。本文阐述了儿童难治性MG在治疗方面的最新进展，包括新的生物制剂，如补体抑制剂、FcRn抑制剂、靶向B细胞药物等。
Abstract: Myasthenia gravis (MG) is an autoimmune disease mediated by cellular immunity, humoral immunity, complement and cytokines, which causes neuromuscular junction transmission disorders. Pediatric MG is different from adult MG in treatment. However, there is still a lack of a unified treatment plan for refractory MG in children. In recent years, the diagnosis and treatment of pediatric refractory MG have brought revolutionary changes, with the further understanding of the pathogenesis of MG, the development and application of new drugs, and the formation of new concepts. This article reviews recent advances in the treatment of pediatric refractory MG, including new biologics such as complement inhibitors, FcRn inhibitors, and B-cell targeting drugs.
文章引用：甘校铭, 曹洁. 儿童难治性重症肌无力的治疗进展[J]. 临床医学进展, 2026, 16(3): 2836-2845. https://doi.org/10.12677/acm.2026.1631086

参考文献

[1] Howard, J.F. (2017) Myasthenia Gravis: The Role of Complement at the Neuromuscular Junction. Annals of the New York Academy of Sciences, 1412, 113-128. [Google Scholar] [CrossRef] [PubMed]
[2] 徐梓桐, 孙静, 王满侠. 补体在重症肌无力发病及靶向治疗中的研究进展[J]. 中国神经免疫学和神经病学杂志, 2024, 31(3): 212-216.
[3] 中国免疫学会神经免疫分会. 中国重症肌无力诊断和治疗指南(2020版) [J]. 中国神经免疫学和神经病学杂志, 2021, 28(1): 1-12.
[4] 欧瑞阳, 黄雅舒. 自身免疫抗体在重症肌无力发生发展的研究进展[J]. 中国实用神经疾病杂志, 2024, 27(6): 789-792.
[5] Ramdas, S., Painho, T., Vanegas, M.I., Famili, D.T., Lim, M.J. and Jungbluth, H. (2024) Targeted Treatments for Myasthenia Gravis in Children and Adolescents. Pediatric Drugs, 26, 719-740. [Google Scholar] [CrossRef] [PubMed]
[6] Tran, C., Biswas, A., Mendoza, M., Katzberg, H., Bril, V. and Barnett, C. (2020) Performance of Different Criteria for Refractory Myasthenia Gravis. European Journal of Neurology, 28, 1375-1384. [Google Scholar] [CrossRef] [PubMed]
[7] Mantegazza, R. and Antozzi, C. (2018) When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies. Therapeutic Advances in Neurological Disorders, 11, 1-11. [Google Scholar] [CrossRef] [PubMed]
[8] 中国罕见病联盟神经罕见病专业委员会, 中国罕见病联盟重症肌无力协作组, 中华医学会神经病学分会神经肌肉病学组. 中国难治性全身型重症肌无力诊断和治疗专家共识(2024版) [J]. 中华神经科杂志, 2024, 57(8): 840-847
[9] Sanders, D.B., Wolfe, G.I., Benatar, M., Evoli, A., Gilhus, N.E., Illa, I., et al. (2016) International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary. Neurology, 87, 419-425. [Google Scholar] [CrossRef] [PubMed]
[10] Munot, P., Robb, S.A., Niks, E.H., Palace, J., Munot, P., Palace, J., et al. (2020) 242nd ENMC International Workshop: Diagnosis and Management of Juvenile Myasthenia Gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscular Disorders, 30, 254-264. [Google Scholar] [CrossRef] [PubMed]
[11] Mantegazza, R., Vanoli, F., Frangiamore, R. and Cavalcante, P. (2020) Complement Inhibition for the Treatment of Myasthenia Gravis. ImmunoTargets and Therapy, 9, 317-331. [Google Scholar] [CrossRef] [PubMed]
[12] Tice, J.A., Touchette, D.R., Lien, P., Agboola, F., Nikitin, D. and Pearson, S.D. (2022) The Effectiveness and Value of Eculizumab and Efgartigimod for Generalized Myasthenia Gravis. Journal of Managed Care & Specialty Pharmacy, 28, 119-124. [Google Scholar] [CrossRef] [PubMed]
[13] Brandsema, J.F., Ginsberg, M., Hoshino, H., Mimaki, M., Nagata, S., Rao, V.K., et al. (2024) Eculizumab in Adolescent Patients with Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. Pediatric Neurology, 156, 198-207. [Google Scholar] [CrossRef] [PubMed]
[14] Vu, T., Meisel, A., Mantegazza, R., Annane, D., Katsuno, M., Aguzzi, R., et al. (2023) Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. Neurology and Therapy, 12, 1435-1438. [Google Scholar] [CrossRef] [PubMed]
[15] Meisel, A., Annane, D., Vu, T., Mantegazza, R., Katsuno, M., Aguzzi, R., et al. (2023) Long-Term Efficacy and Safety of Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Open-Label Extension. Journal of Neurology, 270, 3862-3875. [Google Scholar] [CrossRef] [PubMed]
[16] Tang, G., Tang, Y., Dhamnaskar, K., Hoarty, M.D., Vyasamneni, R., Vadysirisack, D.D., et al. (2023) Corrigendum: Zilucoplan, a Macrocyclic Peptide Inhibitor of Human Complement Component 5, Uses a Dual Mode of Action to Prevent Terminal Complement Pathway Activation. Frontiers in Immunology, 14, Article ID: 1213920. [Google Scholar] [CrossRef] [PubMed]
[17] Howard, J.F., Bresch, S., Genge, A., Hewamadduma, C., Hinton, J., Hussain, Y., et al. (2023) Safety and Efficacy of Zilucoplan in Patients with Generalised Myasthenia Gravis (RAISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Neurology, 22, 395-406. [Google Scholar] [CrossRef] [PubMed]
[18] Edmundson, C. and Guidon, A.C. (2019) Eculizumab: A Complementary Addition to Existing Long‐term Therapies for Myasthenia Gravis. Muscle & Nerve, 60, 7-9. [Google Scholar] [CrossRef] [PubMed]
[19] Hehir, M.K. and Li, Y. (2022) Diagnosis and Management of Myasthenia Gravis. Continuum, 28, 1615-1642. [Google Scholar] [CrossRef] [PubMed]
[20] Zhen, C., Hou, Y., Zhao, B., Ma, X., Dai, T. and Yan, C. (2022) Efficacy and Safety of Rituximab Treatment in Patients with Idiopathic Inflammatory Myopathies: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 13, Article ID: 1051609. [Google Scholar] [CrossRef] [PubMed]
[21] Molimard, A., Gitiaux, C., Barnerias, C., Audic, F., Isapof, A., Walther-Louvier, U., et al. (2022) Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience. Neurology, 98, e2368-e2376. [Google Scholar] [CrossRef] [PubMed]
[22] 佟语浓, 魏翠洁, 杨小玲, 等. 利妥昔单抗治疗儿童重症肌无力的效果及安全性[J]. 中华儿科杂志, 2024, 62(11): 1050-1055.
[23] Zingariello, C.D., Elder, M.E. and Kang, P.B. (2020) Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Pediatric Neurology, 111, 40-43. [Google Scholar] [CrossRef] [PubMed]
[24] McAtee, C.L., Lubega, J., Underbrink, K., Curry, K., Msaouel, P., Barrow, M., et al. (2021) Association of Rituximab Use with Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open, 4, e2036321. [Google Scholar] [CrossRef] [PubMed]
[25] Li, T., Zhang, G., Li, Y., Dong, S., Wang, N., Yi, M., et al. (2021) Efficacy and Safety of Different Dosages of Rituximab for Refractory Generalized AChR Myasthenia Gravis: A Meta-Analysis. Journal of Clinical Neuroscience, 85, 6-12. [Google Scholar] [CrossRef] [PubMed]
[26] 国家神经疾病医学中心, 国家传染病医学中心, 上海市医学会神经内科专科分会, 等. 抗CD20单克隆抗体治疗神经免疫相关疾病期间感染管理上海专家建议(2022) [J]. 中华传染病杂志, 2022, 40(2): 65-70.
[27] Papp, K.A., Haraoui, B., Kumar, D., Marshall, J.K., Bissonnette, R., Bitton, A., et al. (2018) Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies. Journal of Cutaneous Medicine and Surgery, 23, 50-74. [Google Scholar] [CrossRef] [PubMed]
[28] 上海市疾病预防控制中心, 杭州市疾病预防控制中心, 苏州市疾病预防控制中心, 等. 特殊健康状态儿童预防接种专家共识之十九-免疫抑制剂与预防接种[J]. 中国实用儿科杂志, 2019, 34(5): 335-336.
[29] Hewett, K., Sanders, D.B., Grove, R.A., Broderick, C.L., Rudo, T.J., Bassiri, A., et al. (2018) Randomized Study of Adjunctive Belimumab in Participants with Generalized Myasthenia Gravis. Neurology, 90, E1425-E1434. [Google Scholar] [CrossRef] [PubMed]
[30] Iorio, R. (2024) Myasthenia Gravis: The Changing Treatment Landscape in the Era of Molecular Therapies. Nature Reviews Neurology, 20, 84-98. [Google Scholar] [CrossRef] [PubMed]
[31] Guo, Q., Huang, Y., Wang, F. and Fang, L. (2023) Case Report: Telitacicept in Severe Myasthenia Gravis: A Case Study with Multiple Autoantibodies. Frontiers in Immunology, 14, Article ID: 1270011. [Google Scholar] [CrossRef] [PubMed]
[32] Nelke, C., Schroeter, C.B., Stascheit, F., Pawlitzki, M., Regner-Nelke, L., Huntemann, N., et al. (2022) Eculizumab versus Rituximab in Generalised Myasthenia Gravis. Journal of Neurology, Neurosurgery & Psychiatry, 93, 548-554. [Google Scholar] [CrossRef] [PubMed]
[33] Wang, G., Kessi, M., Huang, X., Zhang, W., Zhang, C., He, F., et al. (2024) Treatment of Juvenile Myasthenia Gravis with Tacrolimus: A Cohort Study. European Journal of Neurology, 31, e16466. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, Y., Zhang, M., Zhang, L., Zhou, S. and Li, W. (2023) Long-Term Efficacy and Safety of Tacrolimus in Young Children with Myasthenia Gravis. Journal of Clinical Neuroscience, 116, 93-98. [Google Scholar] [CrossRef] [PubMed]
[35] Jiang, A., Hu, Q., Wang, Z. and Wu, F. (2025) Efficacy and Safety of Tacrolimus Therapy in Patients with Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis. Pediatric Neurology, 166, 32-38. [Google Scholar] [CrossRef] [PubMed]
[36] 平静, 洪思琦. 他克莫司治疗儿童重症肌无力研究进展[J]. 儿科药学杂志, 2024, 30(2): 61-64.
[37] Chen, D., Hou, S., Zhao, M., Sun, X., Zhang, H. and Yang, L. (2018) Dose Optimization of Tacrolimus with Therapeutic Drug Monitoring and cyp3a5 Polymorphism in Patients with Myasthenia Gravis. European Journal of Neurology, 25, 1049-e80. [Google Scholar] [CrossRef] [PubMed]
[38] Sossa Melo, C.L., Peña, A.M., Salazar, L.A., Jiménez, S.I., Gómez, E.D., Chalela, C.M., et al. (2019) Autologous Hematopoietic Stem Cell Transplantation in a Patient with Refractory Seropositive Myasthenia Gravis: A Case Report. Neuromuscular Disorders, 29, 142-145. [Google Scholar] [CrossRef] [PubMed]
[39] Beland, B., Hahn, C., Jamani, K., Chhibber, S., White, C., Atkins, H., et al. (2022) Autologous Hematopoietic Stem Cell Transplant for the Treatment of Refractory Myasthenia Gravis with Anti-Muscle Specific Kinase Antibodies. Muscle & Nerve, 67, 154-157. [Google Scholar] [CrossRef] [PubMed]
[40] 中国罕见病联盟神经罕见病专业委员会, 中国罕见病联盟重症肌无力协作组, 中华医学会神经病学分会神经肌肉病学组. 嵌合抗原受体T细胞治疗难治性神经系统自身免疫性疾病专家共识(2025年版) [J]. 中华神经科杂志, 2025, 58(4): 347-358.
[41] Granit, V., Benatar, M., Kurtoglu, M., Miljković, M.D., Chahin, N., Sahagian, G., et al. (2023) Safety and Clinical Activity of Autologous RNA Chimeric Antigen Receptor T-Cell Therapy in Myasthenia Gravis (MG-001): A Prospective, Multicentre, Open-Label, Non-Randomised Phase 1b/2a Study. The Lancet Neurology, 22, 578-590. [Google Scholar] [CrossRef] [PubMed]
[42] Tian, D., Qin, C., Dong, M., Heming, M., Zhou, L., Wang, W., et al. (2024) B Cell Lineage Reconstitution Underlies CAR-T Cell Therapeutic Efficacy in Patients with Refractory Myasthenia Gravis. EMBO Molecular Medicine, 16, 966-987. [Google Scholar] [CrossRef] [PubMed]
[43] Motte, J., Sgodzai, M., Schneider-Gold, C., Steckel, N., Mika, T., Hegelmaier, T., et al. (2024) Treatment of Concomitant Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome with Autologous CD19-Targeted CAR T Cells. Neuron, 112, 1757-1763.e2. [Google Scholar] [CrossRef] [PubMed]
[44] Haghikia, A., Hegelmaier, T., Wolleschak, D., Böttcher, M., Desel, C., Borie, D., et al. (2023) Anti-cd19 CAR T Cells for Refractory Myasthenia Gravis. The Lancet Neurology, 22, 1104-1105. [Google Scholar] [CrossRef] [PubMed]
[45] Morales-Ruiz, V., Juárez-Vaquera, V.H., Rosetti-Sciutto, M., Sánchez-Muñoz, F. and Adalid-Peralta, L. (2022) Efficacy of Intravenous Immunoglobulin in Autoimmune Neurological Diseases. Literature Systematic Review and Meta-Analysis. Autoimmunity Reviews, 21, Article ID: 103019. [Google Scholar] [CrossRef] [PubMed]
[46] 中国免疫学会神经免疫分会. 静脉注射人免疫球蛋白治疗神经系统免疫疾病中国指南[J]. 中国神经免疫学和神经病学杂志, 2022, 29(6): 437-448.
[47] Selcen, D., Dabrowski, E.R., Michon, A.M. and Nigro, M.A. (2000) High-Dose Intravenous Immunoglobulin Therapy in Juvenile Myasthenia Gravis. Pediatric Neurology, 22, 40-43. [Google Scholar] [CrossRef] [PubMed]
[48] Liew, W.K.M., Powell, C.A., Sloan, S.R., Shamberger, R.C., Weldon, C.B., Darras, B.T., et al. (2014) Comparison of Plasmapheresis and Intravenous Immunoglobulin as Maintenance Therapies for Juvenile Myasthenia Gravis. JAMA Neurology, 71, 575-580. [Google Scholar] [CrossRef] [PubMed]
[49] Jacob, S., Mazibrada, G., Irani, S.R., Jacob, A. and Yudina, A. (2021) The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: A Narrative Review. Journal of Neuroimmune Pharmacology, 16, 806-817. [Google Scholar] [CrossRef] [PubMed]
[50] Connelly‐Smith, L., Alquist, C.R., Aqui, N.A., Hofmann, J.C., Klingel, R., Onwuemene, O.A., et al. (2023) Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 38, 77-278. [Google Scholar] [CrossRef] [PubMed]
[51] 中国医师协会儿科医师分会血液净化专业委员会. 儿童血浆置换临床应用专家共识[J]. 中华实用儿科临床杂志, 2018, 33(15): 1128-1135.
[52] Duan, W., Zhou, H., Dong, X., Li, B., Li, Y., Cai, H., et al. (2022) Application of Lymphoplasmapheresis in the Treatment of Severe Myasthenia Gravis. Frontiers in Neurology, 13, Article ID: 1018509. [Google Scholar] [CrossRef] [PubMed]
[53] Liu, C., Liu, P., Ma, M., Yang, H. and Qi, G. (2021) Efficacy and Safety of Double-Filtration Plasmapheresis Treatment of Myasthenia Gravis: A Systematic Review and Meta-Analysis. Medicine, 100, e25622. [Google Scholar] [CrossRef] [PubMed]
[54] 中国免疫学会神经免疫分会. 中国神经免疫病免疫吸附治疗临床应用指南[J]. 中国神经免疫学和神经病学杂志, 2022, 29(2): 81-84.
[55] Howard, J.J., Bril, V., Vu, T., et al. (2021) Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet. Neurology, 20, 526-536.
[56] Bril, V., Druzdz, A., Grosskreutz, J., et al. (2023) Safety and Efficacy of Rozanolixizumab in Patients with Generalised Myasthenia Gravis (MycarinG): A Randomised, Doubleblind, Placebo-Controlled, Adaptive Phase 3 Study. The Lancet. Neurology, 22, 383-394.
[57] Yan, C., Yue, Y., Guan, Y., et al. (2024) Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurology, 81, 336.
[58] Marx, A., Yamada, Y., Simon-Keller, K., Schalke, B., Willcox, N., Ströbel, P., et al. (2021) Thymus and Autoimmunity. Seminars in Immunopathology, 43, 45-64. [Google Scholar] [CrossRef] [PubMed]
[59] 谭群友, 陶绍霖, 刘宝东, 等. 重症肌无力外科治疗中国临床专家共识[J]. 中国胸心血管外科临床杂志, 2022, 29(5): 529-541.
[60] Ng, W.C. and Hartley, L. (2021) Effectiveness of Thymectomy in Juvenile Myasthenia Gravis and Clinical Characteristics Associated with Better Outcomes. Neuromuscular Disorders, 31, 1113-1123. [Google Scholar] [CrossRef] [PubMed]
[61] Coco, D. and Leanza, S. (2023) Robotic Thymectomy: A Review of Techniques and Results. Polish Journal of Cardio-Thoracic Surgery, 20, 36-44. [Google Scholar] [CrossRef] [PubMed]
[62] Na, K.J. and Kang, C.H. (2020) Robotic Thymectomy for Advanced Thymic Epithelial Tumor: Indications and Technical Aspects. Journal of Thoracic Disease, 12, 63-69. [Google Scholar] [CrossRef] [PubMed]
[63] 蒋斌诚, 许宁, 谷志涛, 等. 非治疗性胸腺切除术及胸腺切除对整体健康影响的研究进展[J]. 中国胸心血管外科临床杂志, 2024, 31(8): 1222-1228.
[64] 蔺晓婷, 潘祖林, 刘鹏, 等. 胸腺切除对机体免疫功能影响的长期风险与临床管理[J]. 中国胸心血管外科临床杂志, 2026, 33(2): 211-217.

为你推荐